 |
 |
 |
 |
 |
 |
 |
 |
About Maas Biolab
Maas Biolab is a neuropharmaceutical company
developing a treatment- the use of cyclosporins as neuro-protectants- for chronic neurodegenerative diseases including amyotrophic lateral sclerosis, Alzheimer's, Parkinson's and Huntington's.
NeuroVive Pharmaceutical AB, a Maas Biolab Swedish partner, is developing cyclosporin for treatment of the acute neurological indications of stroke, spinal trauma, and traumatic brain injury.
Maas Biolab’s patent and related intellectual property rights consist
of "new use" patents, formulation patents and production patents
for cyclosporins as neuroprotective agents issued or pending in the USA,
Canada, Australia, New Zealand, and ARIPO (Africa), Europe (EPO), Japan,
China, Russia and Mexico.
Members of the cyclosporin family display powerful neuroprotective properties
in neuro-degeneration by preventing or reducing neuron
cell death, by blocking critical enzymes and free radicals and protecting
the mitochondria. Pre-clinical studies show cyclosporin-A to be the
most powerful known neuroprotectant in ALS
with promise also in Alzheimer's, Huntington's, and Parkinson's diseases.
The robustness of cyclosporin neuroprotection in animal models makes it likely that it will be the first class of drugs to have significant effect in humans. Initially, Maas Biolab intends to undertake further research, drug development, and clinical studies of cyclosporins in ALS, followed by the Alzheimer's, Huntington's and Parkinson's indications.
Neurological
diseases to be treated by Cyclosporin Neuroprotection
Clinical and Scientific Advisory Board